  
Medical researchers are posting optimism in the long fight against cancer as advances were unveiled to combat the disease that continues to rise and remains the second biggest killer in the world.
“Our growing understanding of cancer’s complex behavior is being translated into better, more targeted drugs against a variety of tumors,” Douglas Blayney, president of the American Society of Clinical Oncology (ASCO), said at the group’s annual meeting.
The most encouraging results unveiled in Chicago last week during the world’s biggest gathering of cancer experts demonstrated the growing role of therapies targeting key tumor functions or helping the immune system destroy cancer cells instead of standard chemotherapy.
These advances showed increased rates of survival, particularly among patients with advanced or metastasized cancers, such as melanoma. There are few, if any, treatments against these types of cancers.
An experimental antibody known as ipilimumab activates the immune system’s T cells, which then seek and destroy melanoma cells, instead of targeting the cancer cell itself like previous treatments.
Researchers found the drug was the first to extend the lives of patients with advanced melanoma, the deadliest form of skin cancer. Melanoma cases have climbed faster than any other cancer type over the past 30 years.
Another new experimental drug, crizotinib was shown to shrink tumors in advanced lung cancer patients with a specific type of genetic alteration by neutralizing an enzyme implicated in cancer cell growth, known as anaplastic lymphoma kinase, or ALK.
Lung cancer is the most frequent and deadliest of all cancers worldwide.
Another clinical trial found that long-term treatment with the drug Avastin, which cuts off supply of nutrient-rich blood to tumors, may help control progress of advanced ovarian cancer.
Adding radiation therapy to androgen deprivation therapy (ADT) was also found to cut by 43 percent the risk of death in men suffering from locally advanced or high-risk prostate cancer.
“We really want to improve the quality of life of the patients with fewer side effects and some of these new approaches really accomplished that,” University of Pennsylvania professor of medicine Lynn Schuchter told AFP.
Driving home that point, the ASCO meeting devoted its theme this year to “advancing quality through innovation.”
Despite the progress and improvement of care since president Richard Nixon declared war against cancer in 1971, the disease remains far too frequent in the United States.
The American Cancer Society (ACS) estimates that nearly 1.5 million new cases were recorded in 2009, killing over 560,000 people.
A recent report by the World Health Organization warned the number of cancer deaths could double worldwide by 2030, to reach 13 million.
As industrialized countries struggle to care for an aging population, nearly half of all men and one in three women will be diagnosed with cancer in their lives, according to the ACS.
Several types of cancers — liver, pancreas, ovarian, lung and brain — are particularly lethal and do not respond well to existing therapies.
But the incidence of cancer is tied to lifestyles, placing the onus on prevention efforts.
Nearly 40 percent of the drop in male cancer deaths from 1990 to 2006 owed to a reduction in lung cancer, whose main culprit is smoking.
See below products associated to his article. Thank you.
?
A report published online on June 2, 2010 in the American Journal of Clinical Nutrition reveals a lower risk of developing depression among men and women who consume greater amounts of vitamin B6 and vitamin B12.
Researchers at Rush University Medical Center in Chicago evaluated data from 3,503 participants in the Chicago Health and Aging project, an ongoing study of adults aged 65 and older. Intake of vitamin B6, vitamin B12 and folate was calculated from dietary questionnaire responses. Depression was assessed via the 10 item Center for Epidemiologic Studies Depression scale administered during follow-up interviews conducted between 1997 and 2009.
Four hundred seventy-one participants reported at least 4 depressive symptoms over up to 12 years of follow-up. Adjusted analysis of the data revealed that higher intakes of both vitamin B6 and B12 from food and supplements were associated with decreased depressive symptoms over the course of follow-up. Each additional 10 milligrams of vitamin B6 and 10 micrograms of vitamin B12 intake were associated with a 2% lower risk of developing depressive symptoms per year. No significant benefit was observed in association with B vitamin intake from food alone, nor was an effect found for folate. The authors note that vitamin B12 from food sources has poor bioavailability and absorption, especially in older individuals. They also suggest that “it is possible that folate is associated with the onset of depressive symptoms but only at insufficient concentrations that are below the range of intake that occur in fortified folic acid populations such as the Chicago Health and Aging Project population.”
In their discussion of possible protective mechanisms for the vitamins against depression, the authors remark that a deficiency of vitamin B12 is responsible for a neurological syndrome that includes depressive symptoms, and that pyridoxal 5′-phosphate, the primary biologic form of vitamin B6, is a cofactor in serotonin synthesis, a neurotransmitter that has an important role in mood.
“Our results support the hypotheses that high total intakes of vitamins B6 and B12 are protective of depressive symptoms over time in community-residing older adults,” Kimberly A. Skarupski and her colleagues conclude. “In the assessment and treatment of depressive symptoms in older adults, clinicians and other health care professionals should be mindful of the patient’s nutritional status in general, and whether there are vitamin insufficiencies in these nutrients before treatment.”
See below products associated to his article. Thank you.
 An article published in the June, 2010 issue of the American Journal of Clinical Nutrition describes a clinical trial involving older men and women which found reductions in markers of oxidative stress and inflammation among those who supplemented with zinc. Oxidative stress and chronic inflammation are risk factors for atherosclerosis, and zinc deficiency has been observed in a number of other diseases associated with these conditions, including rheumatoid arthritis, diabetes and cancers. “We previously observed that healthy elderly subjects had increased concentrations of plasma lipid peroxidation byproducts and endothelial cell adhesion molecules compared with concentrations in younger adults,” the authors write in their introduction. “Zinc was proposed to have an atheroprotective function because of its antiinflammatory, antioxidant, and other properties.”
In a double-blinded trial, 40 healthy men and women between the ages of 56 and 83 were randomized to receive 45 milligrams zinc from zinc gluconate or a placebo for 6 months. C-reactive protein (CRP), interleukin-6 and other markers of inflammation were measured before and after treatment, as were malondialdehyde and hydroxyalkenals, which are markers of lipid peroxidation.
Zinc concentrations were higher in the zinc group by the end of the study, while remaining relatively unchanged among those who received the placebo. Plasma antioxidant powers were higher, and malondialdehyde and hydroxyalkenals were lower in the zinc supplemented subjects after 6 months, indicating a reduction in lipid peroxidation. Additionally, plasma C-reactive protein, interleukin-6, and other inflammation-associated factors were reduced among those who received zinc. “To our knowledge, this is the first documentation to show the down-regulation of plasma CRP concentrations by zinc supplementation in human subjects,” the authors remark.
In another experiment involving cell cultures, zinc also reduced indicators of inflammation and lipid peroxidation as well as the activation of nuclear transcription factor kappa-beta, which is involved in the initiation and development of atherosclerosis.
“This study showed that zinc increased antioxidant power and decreased CRP, inflammatory cytokines, adhesion molecules, and oxidative stress markers in elderly subjects after 6 months of supplementation,” the authors write. “These findings suggest that zinc may have a protective effect in atherosclerosis because of its antiinflammatory and antioxidant functions,” they conclude.
See below products associated to his article. Thank you.
 New Haven, Conn. — The molecular caps at the ends of chromosomes that protect humans against cancer and premature cellular aging show a surprising inability to protect themselves against ultraviolet radiation, a new Yale School of Medicine study has found.
Telomeres – the repeat sequences of DNA at the end of chromosomes that act like plastic tips at the end of a shoelace – are much more likely to be damaged by UV radiation than are other common cellular structures, researchers report in the study published online April 29 in the journal PLoS Genetics.
‘This damage is not repaired. It is as if the cell has decided to defer maintenance to the telomeres,’ said Douglas Brash, professor of therapeutic radiology, genetics and dermatology, a researcher for the Yale Cancer Center, and senior author of the study.
As cells divide over a lifetime, telomeres tend to wear down, and the resulting instability of chromosomes can lead to problems such as increased risk of cancer. As telomeres shorten, cells begin to age, deteriorate and eventually die.
Given their importance, scientists expected telomeres to possess robust defense mechanisms. Brash and Yale postdoctoral researcher Patrick Rochette, now assistant professor at Laval University, Quebec, tested the hypothesis by bombarding human cells with ultraviolet radiation. They found 10 times more DNA damage in telomeres than to the p53 gene, to a gene encoding a subunit of the cell’s ribosome or to mitochondrial DNA. And the damage to the telomeres was not repaired.
‘There may be many reasons for this, but it looks like the medicine might be worse than the disease,’ Brash said.
An overly robust response to fix damage at the tips of the chromosome might trigger even bigger problems for the cell – such as causing breaks within double strands of DNA, Brash speculated.
The strategy, however, is not without risk. Over many years, the accumulating damage may make the telomeres harder to copy when the cell divides, eventually leading to cell aging and death.
The National Cancer Institute of the National Institutes of Health funded the work.
CONTACT: Bill Hathaway, Yale University Tel: +1 203 432 1322
See below products associated to his article. Thank you.
 Sexual activity declines in the year after heart attack for patients who don’t get instructions from their doctors about when it’s safe to resume sex, researchers reported at the American Heart Association’s 11th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke (see also Heart Attack).
In a study of 1,184 male and 576 female acute heart attack patients, nearly half the men and about a third of women reported receiving discharge instructions on resuming sexual activity. Even fewer — less than 40 percent of men and less than 20 percent of women — talked about sex with their physicians in the year following their heart attack.
One year after heart attack, more than two thirds of the men reported some sexual activity, and about 40 percent of the women reported sexual activity. Men were 1.3 times and women 1.4 times more likely to report a loss of sexual activity after one year if they didn’t receive information on when to resume sexual activity.
“Sexuality is an important part of life throughout life, and most heart attack patients are sexually active,” said Stacy Tessler Lindau, M.D., lead author of the study and associate professor of obstetrics/gynecology and medicine-geriatrics at the University of Chicago. “For the most part, physicians just aren’t discussing this topic with their patients after a heart attack.”
Most participants were assessed at one month and again at one year following their heart attack regarding level of sexual activity both before and after heart attack. Researchers set up gender-separate models to predict the frequency of sexual activity at one year following a heart attack in those who were sexually active prior to or since their heart attack. Male participants (average age 59 years) were more likely to be married than women participants (average age 61 years) and were more likely to be sexually active prior to the heart attack. Even after adjusting for these differences, patients who had been given instructions about resuming sexual activity at hospital discharge were more likely to engage in such activity over the following year.
The study was part of TRIUMPH (Translational Research Investigating Underlying Disparities in Recovery from Acute Myocardial Infarction: Patients’ Health Status). Participants were asked questions about their sexual activity prior to and after having a heart attack.
“As survival after a heart attack continues to improve, it is important to begin studying the outcomes of patients who survive; their symptoms, function and quality of life,” said John A. Spertus, M.D., M.P.H., Clinical Director of Outcomes Research at Saint Luke’s Mid America Heart Institute/UMKC and Principal Investigator of the TRIUMPH Study. “To date, few studies have examined whether patients who survive a heart attack resume sexual activity.”
“Little is known about what happens to patients’ sexuality and sexual function after a heart attack, particularly for women,” Lindau said. “While most hospitals have a regimented process of presenting discharge information to patients after heart attack, the question of when it’s safe to resume sexual activity after heart attack is not always addressed.”
Even when it’s discussed, the researchers aren’t sure what’s being said. “We don’t yet know the content or value of the instructions patients are receiving,” she said.
The consensus among physicians is that it’s safe to resume sexual activity after a heart attack once the patient feels better and is capable of performing moderate exercise.
“The likelihood of dying during sexual intercourse, even among people who have had a heart attack, is really small,” Lindau said.
Some physicians are reluctant to discuss sex with patients who are older, aren’t married or belong to a conservative religious group, she said. “But in the case of sexuality, stereotypes don’t work. Older patients may not be married but still have an intimate romantic partner.”
Physicians need to bring up the subject, even if it’s not part of a routine discharge check list, because “not raising the question of sexuality leaves the door closed.”
Noting their data are preliminary, Lindau said further study is required to determine what information the patients were given by their physicians, what patients need to know, and how to tailor information for patients so that they will feel free to ask questions and to seek help.
“Often physicians are focused on saving lives, and sexual health may not be valued as much as medications and other treatments to prevent further progression of their coronary disease,” she said. “Doctors need to be proactive and help patients recover their whole lives after heart attack. Physicians need to assess a patient’s sexual history to ensure all aspects of a patient’s physical and emotional well-being are addressed. This is an essential part of healthcare.”
The National Institute on Aging and the National Heart, Lung, and Blood Institute funded the study.
Other co-authors are Kensey Gosch, M.S.; Paul Chan, M.D., M.Sc.; Emily Abramsohn, M.P.H.; Kristen Wroblewski, M.S.; Harlan Krumholz, M.D., M.Sc. and Erica Spatz, M.D. Author disclosures are on the abstract.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.
Keywords: Cardiology, Heart Attack, American Heart Association.
This article was prepared by Physician Business Week editors from staff and other reports. Copyright 2010, Physician Business Week via NewsRx.com.
See below products associated to his article. Thank you.
 SAN LUIS OBISPO, Calif., May 27 /PRNewswire-USNewswire/ — The Chicago Blackhawk team physicians began diagnosing and treating vitamin D deficiency in all Blackhawk players about 18 months ago. Apparently, most players are on 5,000 IU of vitamin D3 per day. To confirm this assertion, simply ask the Blackhawk organization.
After many losing seasons, last year the Blackhawks came out of nowhere to get to the Western conference finals. This year the Blackhawks are playing even better.
According to my sources, improved athletic performance is only one of the benefits for the Blackhawk players. The other is a reduction in the number and severity of lower respiratory tract infections and a reduction in the number and severity of repetitive use injuries.
Six months ago, Runner’s World published a story on vitamin D and athletic performance.
Asp K. Running on D: The “sun vitamin” may boost performance, but you probably aren’t getting enough. Runners World, December 2009.
A year ago, the flagship journal of the American College of Sports Medicine published the evidence that vitamin D would improve athletic performance, including evidence vitamin D played a role in the USSR and East Germany domination of the Olympics in the 1960s, 70s, and early 80s.
Cannell JJ, Hollis BW, Sorenson MB, Taft TN, Anderson JJ. Athletic performance and vitamin D. Med Sci Sports Exerc. 2009 May;41(5):1102-10.
Recently, researchers in England found a direct and strong relationship between muscle power and vitamin D levels in teenage girls.
Ward KA, et al. Vitamin D status and muscle function in post-menarchal adolescent girls. J Clin Endocrinol Metab. 2009 Feb;94(2):559-63.
However, readers of the Vitamin D Council’s newsletter first learned about vitamin D and athletic performance in 2007:
Cannell, JJ. Peak Athletic Performance and Vitamin D. Vitamin D Council Newsletter, March 2007.
If the Blackhawks win the Stanley Cup this year, other teams, from high school to professional, may start paying attention to the vitamin D status of their players. That would be a big boost to the Vitamin D Council’s goal of educating the world about the importance of vitamin D.
Vitamin D Council
CONTACT: John Cannell, MD, The Vitamin D Council, +1-805-712-0440(cell), +1-805-468-2061, jjcannell@vitamindcouncil.org
See below products associated to his article. Thank you.
 After decades of research and multiple failed attempts to find a treatment, the pharmaceutical industry is entering a critical phase in the search for a drug that can slow, or stop, the progression of Alzheimer’s disease.
Drugmakers see huge money-making potential because of the aging population. Alzheimer’s afflicts more than 5 million Americans and is one of the leading causes of death in the United States, according to the Centers for Disease Control and Prevention. The market of patients globally is estimated to rise from about 30 million in 2010 to 120 million by 2050, opening the door to billions of dollars in sales.
There are an unprecedented five drugs being developed to modify the insidious disease that are in the Phase 3 final stage of U.S.-approved clinical trials. These “interventional drugs,” if approved, would be markedly different than what’s available, including Pfizer Inc.’s much-promoted Aricept, which temporarily treats symptoms of Alzheimer’s.
Exactly when one of these experimental treatments might be submitted to the U.S. Food and Drug Administration for approval is unclear, and there is no guarantee they will reach consumers. But researchers and some Wall Street analysts are speculating a disease-modifying product could be on the U.S. market within five years.
“This is really the last stage of scientific study before you actually have a product to put on the market,” said William Thies, chief medical and scientific officer for the Alzheimer’s Association. “It’s really an important mark as to how far we have come. You are now seeing the first maturation of the development of the second-generation of drugs for Alzheimer’s disease.”
One such product being watched closely is a biologic drug derived from plasma that is sold by Deerfield-based Baxter International Inc. as a treatment for immune system disorders.
Last month, researchers led by Dr. Norman Relkin from New York-Presbyterian Hospital/Weill Cornell Medical Center presented a 24-patient study that showed Baxter’s drug, Gammagard, as having promise as an effective therapy for Alzheimer’s patients. Researchers saw a reduced rate of brain shrinkage and improved “thinking abilities” in the 16 patients in the trial who received Gammagard intravenously. Baxter plans to expand the research in a final-stage U.S. clinical trial.
The idea behind Baxter’s drug is that it can help the body’s immune system to clear the brain of amyloid, a sticky, plaquelike substance thought to be key in the development and progression of Alzheimer’s.
Jason Marder, 67, and his wife, Karin, of New York, believe his twice-monthly Gammagard infusions have helped to slow the disease since he started receiving them in 2006 as a patient of Relkin’s in the clinical trial.
“The incredible thing is that there has been no decline in Jason,” said Karin Marder, his wife of 17 years.
The Marders understand that no one can be sure it’s the drug allowing him to enjoy an active lifestyle. And they know about the risks of Gammagard for elderly patients, including heart attack or stroke, and side effects such as rash or changes in blood pressure, doctors say.
The Marders say they’re willing to take the risks after having witnessed the devastating effects of the disease on Jason Marder’s brother, who died in his late 40s.
“I had noticed changes in Jason that were not the normal aging process,” Karin Marder said. “I would be sitting with him and he would say, ‘Didn’t we go to a great movie last night?’ And I would say, ‘We did not go to a movie last night.’”
Jason Marder continues to have similar forgetful conversations. But his wife thinks the episodes would be more frequent and that he would be less independent if he hadn’t been on Gammagard. Seven years since being diagnosed with Alzheimer’s, Jason Marder continues to take the subway from their Manhattan home, go grocery shopping and prepare meals on his own.
“I was close to his brother, Mitchell. We knew the progression, and it was absolutely devastating,” Karin Marder said. “I have seen the decline, and Jason is no longer in decline. With the baby boomers now, this is going to be an epidemic, and we have to do something about it.”
Baxter is not alone in its hunt for an Alzheimer’s therapy. The world’s largest drug companies also have disease-modifying Alzheimer’s treatments in Phase 3 trials and are investing hundreds of millions of dollars in research.
New York-based Pfizer is in collaboration with a subsidiary of New Jersey-based giant Johnson & Johnson to research, develop and commercialize products to treat or prevent neurodegenerative conditions. The venture’s lead compound is bapineuzumab, which uses antibodies to remove amyloid.
“Our bapineuzumab program is a modifying therapy (being studied) with hopes of modifying the course of Alzheimer’s,” said Dr. Steve Romano, a Pfizer vice president and head of medical affairs for the company’s primary care business.
Despite a study two years ago that linked the drug to brain swelling, Pfizer has forged ahead with patient trials of bapineuzumab. The J&J-Pfizer venture hopes to ramp up clinical trials to study up to 4,000 patients worldwide. Analysts say North American trials could be completed in 2012, but the company is not speculating on a potential submission to the FDA.
Pfizer knows the risks too well. In March, a study of Pfizer’s once-promising Alzheimer’s drug Dimebon showed it was no more effective than a placebo in a Phase 3 study. Pfizer said it continues to evaluate Dimebon as a possible Alzheimer’s treatment.
“Even though there have been failures, you have to consider you are looking at novel mechanisms and trying to take the treatment to another level,” Romano said. “There are risks, but they are worth it.”
The last three years have brought other high-profile failures in late-stage trials, such as the drug Flurizan, developed by Myriad Genetics Inc., and Neurochem Inc.’s Alzhemed.
Baxter Chief Executive Bob Parkinson calls the Gammagard-Alzheimer’s project a “wild card,” but analysts who follow the company see it as potentially a blockbuster that could one day generate more than $1 billion in annual sales.
Baxter is proceeding with caution, which industry analysts say is warranted given the study of Gammagard has been on so few patients. A larger study of 360 patients in more than two dozen sites across the country and a recently announced concurrent study over the next two to three years will reveal more about Gammagard’s future as an Alzheimer’s treatment.
“While the Phase 2 results are encouraging for patients who have few clinical options, the sample size was small, and we will need to wait for results from the two Phase 3 studies to have a clear sense of the clinical benefit from this treatment,” said Ben Andrew, an analyst with Chicago investment bank William Blair & Co.
Even faced with the prospect of additional failures, researchers say continued study will help the medical community better understand how drugs can affect the progression of Alzheimer’s. The Weill Cornell trial of Baxter’s drug used magnetic resonance imaging of patients’ brains to provide a more definitive measure showing “less whole-brain atrophy.”
“The use of MRI technology gives us encouragement that the combination of traditional clinical test outcomes and biological markers like those from brain imaging can facilitate Alzheimer’s clinical trials,” Relkin said. “The (use of MRI technology) may increase the accuracy of the tests themselves. This may spur other trials.”
bjapsen@tribune.com
See below products associated to his article. Thank you.
 At the end of a three day journey, on foot, up the fabled Drum Mountain to the Monastery of the Golden Buddha, I learned a gigantic truth about the power of Traditional Chinese Medicine.
Dragging my dear friend and confidant Mark Soderquist, along to witness and record it all, it seemed like we crawled up Drum Mountain on our hands and knees, through the fog that envelopes Drum Mountain continuously.
The Head Professor at the fabled Institute in Shanghai had said “the monks up there live forever, no one ever dies, they CAN’T die.”
This could very well be the famed Holy Grail of all Chinese Medicine and the answer to my prayers in fighting cancer (and something to bring home and share with all of America.)
This magical Kingdom of Longevity is like something from a dream, all set in a Lord of the Rings setting, containing what seemed like the greatest collection of gold Buddhas in all of China. Some of the golden Buddhas were so immense they were laying down on their side. Work, prayers and meditaiton went on all around them. Simply amazing, but let’s move on.
Through our faithful translator and mediator, Shen Yuun who worked at the Instititute and spoke impeccable Hollywood DVD-English, we were introduced to the Head Abbot of the Monsastery and his Number One Assistant, the Monk of all Healing.
“We watch nature in action; Then we eat it.”
What Shen Yuun plucked from the depths of the Abbot’s mind was something of pure genius and totally magic in its simplicity. For thousands of years, the monks had been taught all aspects of life everlasting, and that every answer to all things lay in Nature and the Universe. It was their duty was to observe this, note it all down and adopt as much of it into their daily practice.
In particular, to note very carefully what things they observed in nature – in the air and in the plants, flowers, trees, bushes and leaves – that would keep them alive for as long as possible, maybe even forever.
If a bush or leaf could be boiled into a tea that made you think smarter, deeper, wiser, they wrote all this down and started drinking this tea each day. For more than a millennium, all this wisdom of watching nature in action and then distilling it into a meal or a beverage had become the core of the monastery’s belief, and the reason for their fame and following.
And the reason we were there that fateful day.
The Abbott and his right hand man, the Monk of all Healing, were testament to this belief and quest. They both appeared to be more than one hundred years of age, yet neither one had barely a wrinkle on their face. They had a marvelous twinkling in their eyes that could reach all the way into the darkest soul.
The Mushroom Factory & the Garlic Army
As the Abbott talked, and talked and talked, the Monk of all Healing reverently nodded and grunted in agreement, to emphasise the importance of what we were learning.
The Monk then excused himself and came back ten minutes later with a giant wooden bowl of thick steaming soup, as well as bowls for us all to share. The soup was their daily Soup of all Life, the recipe a guarded secret, but the results were there for us to witness.
Everyone at the monastery, many of them 70, 80 and some even 100 or more years old, was bursting with health, energy and glowing with an extraordianry aura. This monastery had no hospital nearby, nor any jail or lunatic asylum. They weren’t needed. No one got sick, no one went mad and jails were unheard of.
I quickly asked for a second bowl and pressed Shen Yuun if we could know the primary ingredients, as we did not want to insult them by asking for the treasured recipe.
It was very simple – in fact, genius in all of its simplicity. Mushrooms collected from all over Drum Mountain, crushed wild garlic cloves, green tea leaves and the special mineral water from their well. These were not your ordinary, everyday mushrooms, though.
They were both tender and thick at the same time and you had to chew and chew to swallow them. There were mushrooms I’d never heard of before; Agaricus, Cordyceps, Maitake, Chaga, Shiitake and Reishi. All these ‘gifts from Nature’ were profoundly enriching to the body’s immune system.
And the garlic was unlike any other garlic I had tasted before. It was like dynamite in the mouth. (Garlic is famous for its immune-fighting abilities, amongst other attributes.)
The water these were all simmered in was no ordinary water either, it was brimming with minerals and trace minerals elements in a chemical balance identical to body plasma.
As we said our thanks for the immense hospitality and made a donation to the monastery and its ongoing work, I said to myself that one day I would bring this meal and this message to America in some shape or form. It became an important part of my personal fight against cancer and I wanted to be able to share it with everyone.
5000 Years in the Making – From the Monastery to You
After a 5000 year journey, today we introduce to you one of Traditional Chinese Medicine’s greatest secrets.
It is very possibly the most powerful immune dysfunction formulation ever released.We have incorporated everything we learned in China up on Drum Mountain, and more.
The “and more” is the use of Garlic (by itself a proven cancer-fighting compound) as a “factory” to incubate and absorb the miracle mineral Selenium into its cellular structure.
What I have always theorized is if we used plants to absorb and assimilate the mineral compounds, then these vital elements would be instantly recognized and quickly assimilated by the body. And the results would be dramatic!
We devised a way to grow garlic in a special “Hydroponic Chamber”, where the water is saturated in vital nutrients and minerals, and in particular a high concentration of Selenium. As the garlic absorbs these nutrients from the water, it bursts forth with flavonoids, and is now super-potentiated with Selenium.
And you are getting it for the first time – it simply is not available anywhere else.
And yes, the “hydroponic” process is patent pending for all this right now. (Greedy thieves, be warned.)
See below products associated to his article. Thank you.
TCM-c (Chinese Medicinal Mushrooms)
 Startling Statistics:
“Rates of Stroke, Diabetes, Heart Disease and Childhood Obesity were found to be 70% higher in neighborhoods the closest to a fast food outlet.”
Our children are being subjected to a highly sophisticated, mass-marketing campaign to eat more and more junk-food.
And school lunches aren’t much help either, which is why First Lady Michelle Obama last month launched an initiative to fight Childhood Obesity.
The implications are terrifying:
declining educational performance & learning disabilities
mental disorders like attention deficit syndrome now at epidemic proportions
massive instances of obesity, leukemia, cancer, diabetes and heart disease
All are evidence of a massive decline in our children’s health and well being. And violence on a scale unheard of in my childhood is now totally commonplace in our schools.
But how do you as a parent cope?
We’ve developed a great tasting, chewable tablet called Kid’s Mins & Vits, in Orange Splash and Berry Blast flavors, that contain the key minerals found in our Life Transfusion Liquid Mineral Complex, along with a blockbuster collection of vitamins A, B, C, D, E, and other key nutrients like Lycopene for its antioxidant powers, Lutein to nourish young eyes and extra Chromium to reduce sweet cravings.
It’s like a nutritional candy but without all the dangerous sugar and additives. It means you can rest assured that with two or three chewable tablets each day, your kids will be getting the essentials their bodies need to fight disease and stay healthy.
I remember when my girls were little how hard it was to get them to eat a balanced diet, particularly vegetables. Kid’s Mins & Vits is a nutritional insurance policy that will provide your child with all the basic essentials to proper nutrition to support their rapidly growing bodies.
As a parent, you can’t be there every second of every day to monitor what they eat and drink. But with our Kid’s Mins & Vits, you know that at least the basics are being provided. Besides, kids love the taste – they think they are eating candy.
“My now 3yr old son loves Kids Mins. He likes to eat 2 or 3 at a time! I started him on these when he was about 6 months old. At the time I had to smash them nearly into a powder and coat pieces of Banana to feed him the Kids Mins as he had no teeth. I don’t know if it’s the kids mins or not, but his health, attitude, intelligence, etc has been and continues to be excellent.”
J Sage – Las Vegas, NV
Young Kids with “Old” Diseases
In every catastrophe, there is a “tip of the iceberg” that tells you in advance of something very serious that is about to happen. With our young children, this “tip of the iceberg” is the frightening incidence of diseases that were once the domain of middle-age or the senior years.
60% or more of school age kids are on mind-altering, stupefying Ritalin for ADD/ADHD
Diabetes now strikes kids from 4 years of age upwards
Arthritis, Leukemia and AIDS were almost never associated with children until recently
High cholesterol and heart disease were once “adults-only” diseases
Now all of these and more are in our children!
What has gone so disturbingly wrong in such a short period of time? Just take a look at what is on TV these days!
Junk Food Culture Driven by Junk TV Propaganda
Diet for the body and the mind is the answer to this nightmare. Food is the most important way to keep a child’s body and defense mechanisms working. Pathogenic organisms and viruses are everywhere. Not just in our junk food but also in our “junk TV”.
Massively bankrolled propaganda campaigns devised by Madison Avenue, with battalions of research insight into the workings of a child’s mind, make the consumption of disease generating, sugar and fat-laden junk food a “wild and exciting adventure”.
Take a trip to a school playground or the mall and count the number of skinny kids you can find. You’ll be lucky to find one. Most are dreadfully overweight, have early onset diabetes, heart disease and are a breeding ground for cancer or leukemia.
These kids are eating themselves to death. They’re overfed and terribly undernourished. You can help change that with our Kid’s Mins & Vits. If kids in America would take this formula every day, we’d see these diseases stopped in their tracks.
And if we could get the kids away from junk TV programming, into a daily exercise program and maybe attend church once a week, this would turn this country around overnight.
And be a giant investment for our future.
See below products associated to his article. Thank you.
Kid’s Mins & Vitamins – Berry Blast
Kid’s Mins & Vitamins – Orange Splash
 The more alcohol a man consumes, the higher his risk of pancreatic cancer, U.S. researchers suggest.
Researchers did not find the association among women, possibly due to the lower proportion of women who reported heavy or binge drinking, U.S. researchers suggest.
Lead author Dr. Samir Gupta, assistant professor of internal medicine at University of Texas Southwestern Medical Center, who conducted the research while at the University of California, San Francisco, finds men who drank alcohol increased their risk of pancreatic cancer by 1.5 to 6 times compared with those who didn’t drink alcohol or who had less than one drink per month.
For the use of the study, the researchers defined one drink as one can, bottle or 12 ounces of beer; a 4-ounce glass of wine; or one shot of liquor. The heaviest drinkers consumed 21 to 35 drinks per week, while binge drinking was defined as five or more drinks in one episode.
The study did not find a pancreatic cancer/alcohol link in women, perhaps because they often drink fewer drinks compared to men, Gupta says.
“Pancreatic cancer is one of the deadliest cancers, so any risk factor that can be identified and addressed may save lives,” Gupta says. “Our research found that large and frequent amounts of alcohol consumption may be risk factors for pancreatic cancer.”
The findings are published online in Cancer Causes and Control.
United Press International
See below products associated to his article. Thank you.
Our Cancer Related Products
|
